Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix, University of Washington to Co-develop Array-Based Dx for Lymphoma

NEW YORK, Sept. 11 (GenomeWeb News) - CombiMatrix and the Universityof Washingtonplan to co-develop a microarray-based test for diagnosing lymphoma, the two groups said today.

A team of university researchers led by Daniel Sabath and Stephen Schmechel, at the Departments of Laboratory Medicine and Pathology in the Schoolof Medicine, claimed to have identified a subset of genes whose expression pattern can "distinguish the various lymphoma types." The goal of the collaboration, then, is to harness those data and develop array-based diagnostics that detect lymphomas and predict clinical outcome.

To help develop and commercialize a potential product, CombiMatrix has penned an agreement with RationalDiagnostics. Last year, Seattle-based RationalDiagnostics, which was co-founded by Sabath and Schmechel, signed a deal with the Universityof Washingtonand the WashingtonTechnologyCenterthat ultimately helped uncover ways of using microarrays to diagnose lymphoma.


Existing methods of diagnosing lymphoma, which are based on examining tissue biopsies for a small number of markers, are often inaccurate and offer physicians "limited information" about the expected course of a patient's cancer progression.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more